Coca-Cola Q4 Revenue Up 6% on Strong Sales “`

Coca-Cola (NYSE:KO) reported a 6% revenue increase in the fourth quarter, overcoming prior sales volume declines. Despite challenges like increased costs from U.S. aluminum tariffs, Coca-Cola is confident in its capacity to navigate these obstacles while innovating and expanding globally. Coca-Cola's Revenue Growth Outpaces Economic Headwinds President Trump's increase of…

ILIKOS and JCPR Partner to Streamline Bioequivalence/Bioavailability Studies in Jordan

PAPHOS, Cyprus, Feb. 11, 2025 — ILIKOS Consulting Group and the Jordan Center for Pharmaceutical Research (JCPR) have formed a strategic partnership to showcase the benefits of designing and conducting BE/BA studies in Jordan, thereby advancing innovative clinical research nationwide. Partnership Objectives: Highlight the advantages of performing BA/BE clinical trials…

Naoris Protocol Unveils World’s First Post-Quantum DePIN Testnet with Over 2.5 Million Transactions in First Week

WILMINGTON, DE, Feb 12, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, pioneers of Decentralized CyberSecurity, launched their highly anticipated Post-Quantum DePIN Testnet, recording over 2.5 million transactions in the first week. This represents an important step towards a decentralized cybersecurity future, empowering users to secure, earn through a…

The First in China! BLA Submitted for Luzhu Biotech’s Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026

Hongkong – February 11, 2025 – (SeaPRwire) – On Feb. 9, 2025, the official website of the Center for Drug Evaluation, National Medical Products Administration of China indicates that the Biologics License Application (BLA) for Luzhu Biotech’s (2480.HK) biological product for prophylaxis, Recombinant Herpes Zoster Vaccine (CHO Cells), has been accepted. This vaccine is the second…